EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners. Proceeds will advance the company's late-stage infectious disease pipeline.
Amount Raised
$35 Million
Round Type
Series A
Los AngelesBiotechnologyHealth CareTherapeuticsInvestors
Description
EIT Pharma, Inc. has successfully closed an oversubscribed $35 million Series A financing round led by Propel Bio Partners. The funding aims to support the advancement of EIT Pharma's therapies for infectious diseases, particularly lonafarnib for chronic hepatitis D. In addition, it will aid in FDA review activities and future manufacturing and commercial readiness steps
Who to call at EIT Pharma, and when
A new round usually means EIT Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day EIT Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at EIT Pharma, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment EIT Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEIT Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.